BioSig Joins Webull Corporate Connect
June 29 2023 - 8:30AM
BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the
“Company”), a medical technology company delivering unprecedented
accuracy and precision to intracardiac signal visualization, today
announced that it is now actively participating on the Webull
Corporate Connect platform, a specialized channel for direct
investor communication and audience engagement, including Q&A.
“We invite all Webull users to engage with us in direct two-way
communications on our new Corporate Connect channel,” said Ken
Londoner, Chairman, CEO and Founder of BioSig. “Our Company is
deeply committed to transparency and accessibility for retail
investors, and this platform provides an easy way for individual
investors and traders to learn more about our Company and interact
with us directly. We are excited to introduce this unique
community-driven experience to our valued shareholders and
prospective investors.”
Stay up to date on BioSig’s investor dialogue and most recent
developments by downloading the Webull app to your smartphone or
tablet device. Visit the BSGM details page on the app and select
“Company” to see our Corporate Communication Service entrance
banner. Click on the banner to view our frequent information posts
and engage in direct Q&A.
For more information about Webull, please visit
www.webull.com.
About Webull FinancialBrokerage services are
offered through Webull Financial LLC (“Webull Financial”), an
SEC-registered broker-dealer and member of the Financial Industry
Regulatory Authority (FINRA) and the Securities Investor Protection
Corporation (SIPC). Investment advisory services are offered by
Webull Advisors LLC (“Webull Advisors”), a Securities and Exchange
Commission (SEC) registered investment adviser. Webull
Financial and Webull Advisors are affiliates. All investing is
subject to risk, including the possible loss of the money you
invest. Neither entity guarantees profits or protection from
losses. www.webull.com
About BioSig TechnologiesBioSig
Technologies is an advanced medical technology company
bringing never-before-seen insights to the treatment of
cardiovascular arrhythmias. Through collaboration with physicians,
experts, and healthcare leaders across the field of
electrophysiology (EP), BioSig is committed to addressing
healthcare’s biggest priorities—saving time, saving costs, and
saving lives.
The Company’s first product, the PURE EP™ Platform, an FDA
510(k) cleared non-invasive class II device, provides superior,
real-time signal visualization allowing physicians to perform
insight-based, highly targeted cardiac ablation procedures with
increased procedural efficiency and efficacy.
The global EP market is projected to reach $16B in 2028 with an
11.2% growth rate.1
Forward-looking StatementsThis press release
contains “forward-looking statements.” Such statements may be
preceded by the words “intends,” “may,” “will,” “plans,” “expects,”
“anticipates,” “projects,” “predicts,” “estimates,” “aims,”
“believes,” “hopes,” “potential” or similar words. Forward-looking
statements are not guarantees of future performance, are based on
certain assumptions and are subject to various known and unknown
risks and uncertainties, many of which are beyond the Company’s
control, and cannot be predicted or quantified and consequently,
actual results may differ materially from those expressed or
implied by such forward-looking statements. Such risks and
uncertainties include, without limitation, risks and uncertainties
associated with (i) the geographic, social and economic impact of
COVID-19 on our ability to conduct our business and raise capital
in the future when needed, (ii) our inability to manufacture our
products and product candidates on a commercial scale on our own,
or in collaboration with third parties; (iii) difficulties in
obtaining financing on commercially reasonable terms; (iv) changes
in the size and nature of our competition; (v) loss of one or more
key executives or scientists; and (vi) difficulties in securing
regulatory approval to market our products and product candidates.
More detailed information about the Company and the risk factors
that may affect the realization of forward-looking statements is
set forth in the Company’s filings with the Securities and Exchange
Commission (SEC), including the Company’s Annual Report on Form
10-K and its Quarterly Reports on Form 10-Q. Investors and security
holders are urged to read these documents free of charge on the
SEC’s website at http://www.sec.gov. The Company assumes no
obligation to publicly update or revise its forward-looking
statements as a result of new information, future events or
otherwise.
1 Global Market Insights Inc. March 08, 2022
Andrew Ballou
BioSig Technologies, Inc.
Vice President, Investor Relations
55 Greens Farms Road, 1st Floor
Westport, CT 06880
aballou@biosigtech.com
203-409-5444, x133
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Jun 2024 to Jul 2024
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Jul 2023 to Jul 2024